REAL-WORLD BEHAVIORAL CLUSTERING REVEALS THREE ACTIONABLE COPD PATIENT ARCHETYPES FOR TAILORED INTERVENTIONS
Author(s)
Thibaut Goulvent, PhD1, Barthélémy Bourdon Baron Munoz, Health Psychologist2, Quentin Pedron, Health Psychologist2, Mayane Fouquet-Delage, PhD3, Maxime Granata-Georges, Ms4, Gwenaëlle Jacquand, Ms1, Eric Salone Salone, President5.
1Digital Health & Innovation, AstraZeneca France, Courbevoie, France, 2Hajime.AI, Paris, France, 3Patient Advocacy Groups, AstraZeneca France, Courbevoie, France, 4Public Affairs, AstraZeneca France, Courbevoie, France, 5Association Josiane Salone, PARIS, France.
1Digital Health & Innovation, AstraZeneca France, Courbevoie, France, 2Hajime.AI, Paris, France, 3Patient Advocacy Groups, AstraZeneca France, Courbevoie, France, 4Public Affairs, AstraZeneca France, Courbevoie, France, 5Association Josiane Salone, PARIS, France.
OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) management faces significant adherence challenges, with heterogeneous patient behaviors impacting treatment outcomes.This study aimed to identify distinct behavioral patient profiles among patients with COPD to inform targeted intervention strategies and optimize healthcare resource allocation.
METHODS: A cross-sectional survey was conducted among 1,354French COPD patients (Q1 2026) via patient associations and social media. The questionnaire assessed disease stage awareness, treatment adherence using Theory of PlannedBehavior, healthcare experience, and psychosocial impact. Cluster analysis identified profiles based on disease duration, stage knowledge, motivational dimensions, and perceived follow-up.
RESULTS: Three profiles emerged with critical stage awareness disparities: Profile 1 "Established but Under informed" (28.9%):diagnosed >10 years, yet 24.8% never informed of stage and11.3% unaware stages existed; Stage II (17.1%) and III (16.5%)predominated among informed patients. High adherence (intention:6.6/7) contrasted with limited information perception (3.8/7). Profile2 "Disease-Mobilized" (46.5%): marked Stage IV over representation (15.1% vs. 6.4% Stage I), reflecting advanced disease; elevated activity limitations (6.5/7), social avoidance(6.3/7), loneliness (6/7) and strong diagnostic understanding despite moderate treatment attitude. Profile 3 "Disoriented"(24.5%): recently diagnosed (<2 years: 24.2%), highest stage unawareness (44.9% never told/uncertain/unaware of staging),lower intention (4.1/7), irregular adherence, minimal perceived follow-up, revealing critical early-pathway gaps.
CONCLUSIONS: Stage awareness heterogeneity reveals critical educational gaps requiring profile-specific interventions: structured stage-based education for Profile 1, psychosocial support for Profile 2's advanced patients, and comprehensive diagnostic clarification forProfile 3. Patient associations emerge as strategic partners for disease acculturation and pathway navigation, yet only 9.9%received healthcare professional referrals. Integrating associations into care pathways could optimize resource allocation and address unmet educational needs across all profiles.
METHODS: A cross-sectional survey was conducted among 1,354French COPD patients (Q1 2026) via patient associations and social media. The questionnaire assessed disease stage awareness, treatment adherence using Theory of PlannedBehavior, healthcare experience, and psychosocial impact. Cluster analysis identified profiles based on disease duration, stage knowledge, motivational dimensions, and perceived follow-up.
RESULTS: Three profiles emerged with critical stage awareness disparities: Profile 1 "Established but Under informed" (28.9%):diagnosed >10 years, yet 24.8% never informed of stage and11.3% unaware stages existed; Stage II (17.1%) and III (16.5%)predominated among informed patients. High adherence (intention:6.6/7) contrasted with limited information perception (3.8/7). Profile2 "Disease-Mobilized" (46.5%): marked Stage IV over representation (15.1% vs. 6.4% Stage I), reflecting advanced disease; elevated activity limitations (6.5/7), social avoidance(6.3/7), loneliness (6/7) and strong diagnostic understanding despite moderate treatment attitude. Profile 3 "Disoriented"(24.5%): recently diagnosed (<2 years: 24.2%), highest stage unawareness (44.9% never told/uncertain/unaware of staging),lower intention (4.1/7), irregular adherence, minimal perceived follow-up, revealing critical early-pathway gaps.
CONCLUSIONS: Stage awareness heterogeneity reveals critical educational gaps requiring profile-specific interventions: structured stage-based education for Profile 1, psychosocial support for Profile 2's advanced patients, and comprehensive diagnostic clarification forProfile 3. Patient associations emerge as strategic partners for disease acculturation and pathway navigation, yet only 9.9%received healthcare professional referrals. Integrating associations into care pathways could optimize resource allocation and address unmet educational needs across all profiles.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR89
Topic
Methodological & Statistical Research, Patient-Centered Research, Study Approaches
Topic Subcategory
Adherence, Persistence, & Compliance, Patient Behavior and Incentives
Disease
Mental Health (including addiction), Personalized & Precision Medicine, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)